Polyplus-transfection

The licensing deal grants Roche Glycart access to polyethylenimine for in vitro transfection applications for research purposes.

The company said it will use the funds to advance new siRNA delivery compounds and add 10 new researchers and lab technicians.

The company plans to use the funding to enhance its R&D resources and to hire new researchers and lab technicians.

Metabion will develop custom research reagents and in vitro diagnostics based on Polyplus' ZNA oligonucleotides, which are modified to have increased affinity for nucleic acids while retaining specificity.

The German firm will offer Polyplus-transfection's new ZNA technology, which it said increases the affinity for nucleic acids.

In a new paper, Polyplus-transfection scientists showed that the company's zipped nucleic acids work as hydrolysis probes in quantitative PCR, adding to previous work that demonstrated their use as primers.

The company said the money will primarily be used to support its RNAplus program, which is focused on developing RNAi oligos that do not require delivery reagents.

The firm plans to use the funding to develop oligonucleotide technologies and to add management for the US market.

Sigma-Aldrich will manufacture and sell the French company's oligonucleotides worldwide.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.